Black Women in Clinical Research Joins the Association of Diversity in Clinical Trials as a Supporting Partner
The Association of Diversity in Clinical Trials (AOD) has announced a new partnership agreement with Black Women in Clinical Research (BWICR) allowing their 15,000 members an opportunity to participate in AOD benefits. The mission of the AOD is to establish standards and best practices for the clinical trials industry to improve the representation of diverse participants in clinical trials through the development, integration, and monitoring of quality and consistent diversity methodology across the research industry.
Danielle Mitchell, CEO of BWICR, stated, "The mission of the AOD meets our corporate goals in being a part of standardizing best practices for professionals and bringing training and certification forward in a structured and accessible way for our members. This commitment is exciting and will bring value to our industry as a whole."
Diana Foster, PhD, president of the AOD, credits Mitchell's story of having been blocked from entry into clinical research as the impetus behind her organization's mission.
Reference
BLACK WOMEN IN CLINICAL RESEARCH JOINS THE ASSOCIATION OF DIVERSITY IN CLINICAL TRIALS AS A SUPPORTING PARTNER BRINGING 15,000 MEMBERS TO PARTICIPATE IN AOD MEMBERSHIP. (2023, June 21). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
